Libtayo® (cemiplimab) approved by the european commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% pd-l1 expression

Tarrytown, n.y. and paris, june 25, 2021 /prnewswire/ --  approval based on a phase 3 trial demonstrating libtayo significantly improved overall survival compared to chemotherapy in advanced nsclc that included challenging-to-treat patient populations libtayo now approved by the european commission for three advanced cancers regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced that the european commission (ec) has approved the pd-1 inhibitor libtayo® (cemiplimab) for the first-line treatment of adults with non-small cell lung cancer (nsclc) whose tumor cells have ≥50% pd-l1 expression and no egfr, alk or ros1 aberrations.
REGN Ratings Summary
REGN Quant Ranking